Navigation Links
Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board
Date:8/22/2007

DANBURY, Conn., Aug. 22 /PRNewswire-FirstCall/ -- Biodel, Inc. (Nasdaq: BIOD) today announced the addition of Ralf Rosskamp, M.D., to its Scientific Advisory Board (SAB).

Dr. Rosskamp was previously the Executive Vice President of Research and Development at Kos Pharmaceuticals, where he managed all research and development activities until Kos was acquired by Abbott Laboratories. Dr. Rosskamp's accomplishments at Kos include building an integrated research and development organization, globally expanding Kos's clinical research organization and assisting in the approval of four supplemental new drug applications.

"We are extremely honored to have Dr. Rosskamp join our SAB," said Dr. Solomon Steiner, CEO and Chairman of Biodel. "Dr. Rosskamp played an integral role in bringing insulin analogs to the market. His wealth of knowledge and clinical experience in the field of endocrinology will significantly contribute to the development of VIAject(TM), VIAtab(TM) and our two osteoporosis product candidates."

"I am delighted to join Biodel's SAB, especially at such an exciting time for the Company," said Dr. Rosskamp. "Biodel has created an innovative, injectable human insulin for diabetics and has made great progress in the clinical development of VIAject(TM). I look forward to collaborating with the Biodel team in their efforts to bring safer and more effective treatments to the diabetic patient population."

Prior to joining Kos, Dr. Rosskamp held prominent positions for thirteen years at Aventis Pharmaceuticals, a lead-developer of endocrinology products. At Aventis, Dr. Rosskamp was responsible for achieving FDA/EMEA approval of Lantus(R), the best-selling basal insulin analog and coordinating the clinical trials for Apidra(R), a rapid-acting insulin analog. In addition, Dr. Rosskamp managed the approval process for Actonel(R) Once-a-Week, which prevents and treats post-menopausal osteoporosis, and aided in completing the Phase III study
'/>"/>

SOURCE Biodel, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...eMarbleEnergyCorp.announcedtodaythatthecompanyandt...lyawarded$2millionbyWashingtonState,sCommunityEcon...nershiptoconstructthestate,sfirstspecialtybiochemi...tmentwillsignificantlyspeedthedevelopmentofourbior...dBlueMarbleEnergyCEOKellyOgilvie."Wearegratefultot...
(Date:11/24/2009)...etforpatientswithadvanced-stage,orrecurrentendomet...rstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ...usedonendocrinetherapyandoncology,todayannouncedpo...ytotoxicpeptideconjugate,AEZS-108(formerlyAN-152),....Inapersonalizedhealthcareapproach,thestudyselecte...
(Date:11/24/2009)...rstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglo...edthatithassubmittedaMAAtotheEuropeanMedicinesAgen...enttherapyindevelopment,forthetreatmentofType1Gauc...elaglucerasealfathathasbeensubmitted,withprevious,...donaglobalsupplyshortageofthecurrentlyapprovedandm...
(Date:11/24/2009)...swire-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX ...tiveChairman,willpresentatthe21stAnnualPiperJaffra...er1,2009at10:00a.m.ET. ,, Toaccesstheliveandsub...InvestorRelationssectionofGenomicHealth,swebsiteat...othewebsiteatleast15minutespriortothebeginningofth...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2
...: SHP,NASDAQ: SHPGY ), the global specialty biop...ion agreement with GlaxoSmithKline plc (NYSE: GS...apsules CII with the aim of,improving recognition ...greement covers the United States and will more th...ales effort for VYVANSE by adding over 600 sales,r...
...eted product, a new vaccine against Japanese Encep... - Commercial product launch in the U.S. planned f...E: ICLL) today announced that the U.S. Food and Dr...vaccine for the prevention of Japanese Encephaliti...vaccine - the only such product currently manufact...
...nsulting US, a division of London-based Double Hel...ent of Ann Stuchiner to the position of Vice Presi... highly experienced strategic pricing, reimburseme...perience across the healthcare industry, which pro...n the pharmaceutical, biotechnology and medical de...
Other Biology Technology:Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife Con...evealing that the last remaining population of Sib... to the rising tide of poaching and habitat loss. ...rm Russian officials of what needs to be done to p...t cat. , The report was released by...
(Date:11/24/2009)... (November 24, 2009) New research on bacterial co...tems reveals predictable temporal patterns, sugges...s markers for monitoring climate change in the pol... Proceedings of the National Academy of Sciences ... the six rivers shifted synchronously over time, c...
(Date:11/23/2009)...C. The community-associated strain of the deadly ...nt to most common antibioticsposes a far greater h...ts way into hospitals, according to a study in the... , The new threat is easily picked up in fitnes...s increased the overall burden of MRSA within hosp...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 1Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 2GENova appoints Director of Asian business development 56661 1GENova appoints Director of Asian business development 56661 2Vita Tech International Inc Donates One Ton of Vitamins To Polio Treatment Centers in Guinea West Africa 13950 1
...niversity of Minnesota researchers have found a gr... are proven to turn on T-cells, cells that help fi... the May 2006 issue of the journal Immunity, relea...f cells and immune response will help in studying ... the gastrointestinal system," said Stephen McSorl...
...ealthy coral reefs of Madagascar,s northeast coast...er ocean temperatures attributed to global climate...egion. , The survey of a previously unexplored reg...International and its partners documented a much g...e fish species believed new to science and 17 othe...
...n electronic device designed to "zap" away migrain...lief for millions of people who suffer from the de...at the experimental device appears to be effective...ing the onset of the migraine. , The study, led ...ogy investigators, was presented Thursday (6/22) a...
Other Biology News:Healthy coral reefs of Madagascar resisting damage from climate change 2Device effective in zapping the pain out of migraines 2
RNA 6000 Nano Chip Kit from Agilent Technologies
Mouse Anti-Human ALPK3 Monoclonal Antibody, Unconjugated, Clone 4G4 from Abnova Corporation
...Lines ,High Quality, Functionally-Validated, Ion C...or having a critical role in nerve and muscle func... CNS and the heart. Drugs that modulate ion channe...ch as neuropathic pain, cardiac arrhythmia, hypert...
Mouse Anti-Human CD320 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: